Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS

Plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time

Gianfranco Meduri, S. Headley, G. Kohler, F. Stentz, Elizabeth Tolley, Reba Umberger, K. Leeper

Research output: Contribution to journalArticle

486 Citations (Scopus)

Abstract

Background: Inflammatory cytokines have been related to the development of adult respiratory distress syndrome (ARDS), shock, and multiple organ dysfunction syndrome (MODS). We tested the hypothesis that unfavorable outcome in patients with ARDS is related to the presence of a persistent inflammatory response. For this purpose, we evaluated the behavior of inflammatory cytokines during progression of ARDS and the relationship of plasma inflammatory cytokines with clinical variables and outcome. Methods: We prospectively studied 27 consecutive patients with severe medical ARDS. Plasma levels of tumor necrosis factor alpha (TNF-α) and interleukins (ILs) 1β, 2, 4, 6, and 8 were measured (enzyme-linked immunosorbent assay [ELISA] method) on days 1, 2, 3, 5, 7, 10, and 12 of ARDS and every third day thereafter while patients were receiving mechanical ventilation. Subgroups of patients were identified based on outcome, cause of ARDS, presence or absence of sepsis, shock, and MODS at the time ARDS developed. Subgroups were compared for levels of plasma inflammatory cytokines on day 1 of ARDS and over time. Results: Of the 27 patients, 13 survived ICU admission and 14 died (a mortality rate of 52%). Overall mortality was higher in patients with sepsis (86 vs 38%, p<0.02). The mean initial plasma levels of TNF-α, IL- 1β, IL-6, and IL-8 were significantly higher in nonsurvivors (p<0.0001) and in those patients with sepsis (p<0.0001). Plasma levels of IL-1β (p<0.01) and IL-6 (p=0.03) were more strongly associated with patient outcome than cause of ARDS (p=0.8), lung injury score (LIS), APACHE II score, sepsis (p=0.16), shock, or MODS score. Plasma levels of TNF-α, IL-1β, IL-6, and IL-8 remained significantly elevated over time (p<0.0001) in those who died. Although it was the best early predictor of death (p<0.001), plasma IL-2>200 pg/mL lost its usefulness after the first 48 h. A plasma IL-1β or IL-6 level >400 pg/mL on any day in the first week of ARDS was associated with a low likelihood of survival. Conclusions: Our findings indicate that unfavorable outcome in acute lung injury is related to the degree of inflammatory response at the onset and during the course of ARDS. Patients with higher plasma levels of TNF-α, IL-1β, IL-6, and IL-8 on day 1 of ARDS had persistent elevation of these inflammatory cytokines over time and died. Survivors had lesser elevations of plasma inflammatory cytokines on day 1 of ARDS and a rapid reduction over time. Plasma IL-1β and IL-6 levels were consistent and efficient predictors of outcome.

Original languageEnglish (US)
Pages (from-to)1062-1073
Number of pages12
JournalChest
Volume107
Issue number4
DOIs
StatePublished - Jan 1 1995

Fingerprint

Adult Respiratory Distress Syndrome
Interleukin-1
Interleukin-6
Cytokines
Multiple Organ Failure
Shock
Sepsis
Tumor Necrosis Factor-alpha
Mortality
Acute Lung Injury
Interleukin-8
Artificial Respiration
Interleukin-2
Survivors
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{2ecce9fcbd5345589591680960ac98cb,
title = "Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: Plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time",
abstract = "Background: Inflammatory cytokines have been related to the development of adult respiratory distress syndrome (ARDS), shock, and multiple organ dysfunction syndrome (MODS). We tested the hypothesis that unfavorable outcome in patients with ARDS is related to the presence of a persistent inflammatory response. For this purpose, we evaluated the behavior of inflammatory cytokines during progression of ARDS and the relationship of plasma inflammatory cytokines with clinical variables and outcome. Methods: We prospectively studied 27 consecutive patients with severe medical ARDS. Plasma levels of tumor necrosis factor alpha (TNF-α) and interleukins (ILs) 1β, 2, 4, 6, and 8 were measured (enzyme-linked immunosorbent assay [ELISA] method) on days 1, 2, 3, 5, 7, 10, and 12 of ARDS and every third day thereafter while patients were receiving mechanical ventilation. Subgroups of patients were identified based on outcome, cause of ARDS, presence or absence of sepsis, shock, and MODS at the time ARDS developed. Subgroups were compared for levels of plasma inflammatory cytokines on day 1 of ARDS and over time. Results: Of the 27 patients, 13 survived ICU admission and 14 died (a mortality rate of 52{\%}). Overall mortality was higher in patients with sepsis (86 vs 38{\%}, p<0.02). The mean initial plasma levels of TNF-α, IL- 1β, IL-6, and IL-8 were significantly higher in nonsurvivors (p<0.0001) and in those patients with sepsis (p<0.0001). Plasma levels of IL-1β (p<0.01) and IL-6 (p=0.03) were more strongly associated with patient outcome than cause of ARDS (p=0.8), lung injury score (LIS), APACHE II score, sepsis (p=0.16), shock, or MODS score. Plasma levels of TNF-α, IL-1β, IL-6, and IL-8 remained significantly elevated over time (p<0.0001) in those who died. Although it was the best early predictor of death (p<0.001), plasma IL-2>200 pg/mL lost its usefulness after the first 48 h. A plasma IL-1β or IL-6 level >400 pg/mL on any day in the first week of ARDS was associated with a low likelihood of survival. Conclusions: Our findings indicate that unfavorable outcome in acute lung injury is related to the degree of inflammatory response at the onset and during the course of ARDS. Patients with higher plasma levels of TNF-α, IL-1β, IL-6, and IL-8 on day 1 of ARDS had persistent elevation of these inflammatory cytokines over time and died. Survivors had lesser elevations of plasma inflammatory cytokines on day 1 of ARDS and a rapid reduction over time. Plasma IL-1β and IL-6 levels were consistent and efficient predictors of outcome.",
author = "Gianfranco Meduri and S. Headley and G. Kohler and F. Stentz and Elizabeth Tolley and Reba Umberger and K. Leeper",
year = "1995",
month = "1",
day = "1",
doi = "10.1378/chest.107.4.1062",
language = "English (US)",
volume = "107",
pages = "1062--1073",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS

T2 - Plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time

AU - Meduri, Gianfranco

AU - Headley, S.

AU - Kohler, G.

AU - Stentz, F.

AU - Tolley, Elizabeth

AU - Umberger, Reba

AU - Leeper, K.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background: Inflammatory cytokines have been related to the development of adult respiratory distress syndrome (ARDS), shock, and multiple organ dysfunction syndrome (MODS). We tested the hypothesis that unfavorable outcome in patients with ARDS is related to the presence of a persistent inflammatory response. For this purpose, we evaluated the behavior of inflammatory cytokines during progression of ARDS and the relationship of plasma inflammatory cytokines with clinical variables and outcome. Methods: We prospectively studied 27 consecutive patients with severe medical ARDS. Plasma levels of tumor necrosis factor alpha (TNF-α) and interleukins (ILs) 1β, 2, 4, 6, and 8 were measured (enzyme-linked immunosorbent assay [ELISA] method) on days 1, 2, 3, 5, 7, 10, and 12 of ARDS and every third day thereafter while patients were receiving mechanical ventilation. Subgroups of patients were identified based on outcome, cause of ARDS, presence or absence of sepsis, shock, and MODS at the time ARDS developed. Subgroups were compared for levels of plasma inflammatory cytokines on day 1 of ARDS and over time. Results: Of the 27 patients, 13 survived ICU admission and 14 died (a mortality rate of 52%). Overall mortality was higher in patients with sepsis (86 vs 38%, p<0.02). The mean initial plasma levels of TNF-α, IL- 1β, IL-6, and IL-8 were significantly higher in nonsurvivors (p<0.0001) and in those patients with sepsis (p<0.0001). Plasma levels of IL-1β (p<0.01) and IL-6 (p=0.03) were more strongly associated with patient outcome than cause of ARDS (p=0.8), lung injury score (LIS), APACHE II score, sepsis (p=0.16), shock, or MODS score. Plasma levels of TNF-α, IL-1β, IL-6, and IL-8 remained significantly elevated over time (p<0.0001) in those who died. Although it was the best early predictor of death (p<0.001), plasma IL-2>200 pg/mL lost its usefulness after the first 48 h. A plasma IL-1β or IL-6 level >400 pg/mL on any day in the first week of ARDS was associated with a low likelihood of survival. Conclusions: Our findings indicate that unfavorable outcome in acute lung injury is related to the degree of inflammatory response at the onset and during the course of ARDS. Patients with higher plasma levels of TNF-α, IL-1β, IL-6, and IL-8 on day 1 of ARDS had persistent elevation of these inflammatory cytokines over time and died. Survivors had lesser elevations of plasma inflammatory cytokines on day 1 of ARDS and a rapid reduction over time. Plasma IL-1β and IL-6 levels were consistent and efficient predictors of outcome.

AB - Background: Inflammatory cytokines have been related to the development of adult respiratory distress syndrome (ARDS), shock, and multiple organ dysfunction syndrome (MODS). We tested the hypothesis that unfavorable outcome in patients with ARDS is related to the presence of a persistent inflammatory response. For this purpose, we evaluated the behavior of inflammatory cytokines during progression of ARDS and the relationship of plasma inflammatory cytokines with clinical variables and outcome. Methods: We prospectively studied 27 consecutive patients with severe medical ARDS. Plasma levels of tumor necrosis factor alpha (TNF-α) and interleukins (ILs) 1β, 2, 4, 6, and 8 were measured (enzyme-linked immunosorbent assay [ELISA] method) on days 1, 2, 3, 5, 7, 10, and 12 of ARDS and every third day thereafter while patients were receiving mechanical ventilation. Subgroups of patients were identified based on outcome, cause of ARDS, presence or absence of sepsis, shock, and MODS at the time ARDS developed. Subgroups were compared for levels of plasma inflammatory cytokines on day 1 of ARDS and over time. Results: Of the 27 patients, 13 survived ICU admission and 14 died (a mortality rate of 52%). Overall mortality was higher in patients with sepsis (86 vs 38%, p<0.02). The mean initial plasma levels of TNF-α, IL- 1β, IL-6, and IL-8 were significantly higher in nonsurvivors (p<0.0001) and in those patients with sepsis (p<0.0001). Plasma levels of IL-1β (p<0.01) and IL-6 (p=0.03) were more strongly associated with patient outcome than cause of ARDS (p=0.8), lung injury score (LIS), APACHE II score, sepsis (p=0.16), shock, or MODS score. Plasma levels of TNF-α, IL-1β, IL-6, and IL-8 remained significantly elevated over time (p<0.0001) in those who died. Although it was the best early predictor of death (p<0.001), plasma IL-2>200 pg/mL lost its usefulness after the first 48 h. A plasma IL-1β or IL-6 level >400 pg/mL on any day in the first week of ARDS was associated with a low likelihood of survival. Conclusions: Our findings indicate that unfavorable outcome in acute lung injury is related to the degree of inflammatory response at the onset and during the course of ARDS. Patients with higher plasma levels of TNF-α, IL-1β, IL-6, and IL-8 on day 1 of ARDS had persistent elevation of these inflammatory cytokines over time and died. Survivors had lesser elevations of plasma inflammatory cytokines on day 1 of ARDS and a rapid reduction over time. Plasma IL-1β and IL-6 levels were consistent and efficient predictors of outcome.

UR - http://www.scopus.com/inward/record.url?scp=0028898380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028898380&partnerID=8YFLogxK

U2 - 10.1378/chest.107.4.1062

DO - 10.1378/chest.107.4.1062

M3 - Article

VL - 107

SP - 1062

EP - 1073

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -